Tramadol reclassified as a controlled drug

The Home Office has updated the legal classification of tramadol, lisdexamfetamine, zopiclone and zaleplon.

Tramadol's dual-action pharmacological profile increases the potential for adverse effects, especially in overdose | SCIENCE PHOTO LIBRARY
Tramadol's dual-action pharmacological profile increases the potential for adverse effects, especially in overdose | SCIENCE PHOTO LIBRARY

As of 10th June 2014, tramadol is classified as a Schedule 3 controlled drug. The move is in response to an increase in deaths involving the analgesic.

Other changes to CD legislation also came into force on the same date:

Summary of the changes:

Lisdexamfetamine Tramadol

Zopiclone

Zaleplon
Designation (from 10th June 2014)

Schedule 2

(CD POM)

Schedule 3

(CD No Reg POM)

Schedule 4

(Part I)

Schedule 4

(Part I)

CD prescription requirements Yes Yes No No
Prescription valid for 28 days 28 days 28 days 28 days
Prescription is repeatable No No Yes Yes
Safe custody regulations apply Yes No No No

Ketamine under review

Ketamine remains a Schedule 4 Part 1 drug at present. The Home Office will make a decision on the rescheduling of ketamine later this year following recommendations from the Advisory Council on Misuse of Drugs.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from intelog

New antibiotic prescribing guidance issued for pneumonia

New antibiotic prescribing guidance issued for pneumonia

NICE has published antimicrobial prescribing guidelines...

intelog summary of NICE COPD guidance updated

intelog summary of NICE COPD guidance updated

Prescribers can now consult the quick-reference intelog...

Soft-mist inhaler now available as reusable device

Soft-mist inhaler now available as reusable device

Respimat is now available as a reusable inhaler that...

NICE recommends 'innovative' treatment for type I diabetes

NICE recommends 'innovative' treatment for type I diabetes

Dapagliflozin (Forxiga) has been approved for routine...